Gene Synthesis Firm Sloning Gains $6.8M in European Series E Funding

Nov 06, 2007

NEW YORK (GenomeWeb News) - Sloning Biotechnology said today it has raised €4.7 million ($6.8 million) in Series E venture financing from one new and several previous investors.

Sloning, based in Puchheim, Germany, plans to use the cash to commercialize its Slonomics gene synthesis business internationally and to expand its Slonomax gene mutant library product line.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Main menu